Cyclooxygenase-2 (COX-2) inhibitors are promising anticancer agents but their long-term use at high doses is associated with adverse cardiovascular events. The molecular mechanisms underlying the anticancer or toxic cardiovascular effects of COX-2 inhibitors remain unknown. Here we report that COX-2-selective celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 (DR5) and cooperate with tumor necrosis factor-related apoptosisinducing ligand (TRAIL), the ligand for DR5, to induce apoptosis in COX-2-positive and -negative cancer cells. We also show that both agents engage GADD153/CHOP to transcriptionally upregulate DR5 expression; GADD153/ CHOP is a C/EBP homologous transcription factor implicated in cellular stress response and apoptosis. Based on our results, we propose that (1) these agents appear to mediate their effects, at least in part, by engaging GADD153/CHOP to activate DR5-dependent apoptotic pathway and (2) their regulation of GADD153/CHOP and DR5 expression appears to occur independent of their COX-2 inhibitory effects. Our results also indicate that ON09310 is generally more potent than celecoxib and, at lower concentration, strongly cooperates with TRAIL to induce apoptosis. Taken together, our findings form the basis for future in-depth studies to further explore the utility of TRAIL and/or agonistic anti-DR5 antibodies in combination with low-dose COX-2 inhibitors as a rational approach for cancer prevention and treatment.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for their analgesic, antipyretic and anti-inflammatory effects. NSAIDs mediate their effects by inhibiting two cyclooxygenase isoenzymes, cyclooxygenase (COX)-1 and COX-2 that catalyse the formation of prostaglandins from arachidonic acid (reviewed in Williams et al., 1999) . Unlike COX-1, which is constitutively expressed, COX-2 expression is induced by several agents including the inflammatory cytokines, tumor promoters, growth factors and viral transformation (Williams et al., 1999) . The gastrointestinal side effects due to prolonged use of traditional NSAIDs are believed to occur due to COX-1 inhibition (Williams et al., 1999) , therefore, COX-2-selective inhibitors including celecoxib and rofecoxib have been developed to ameliorate the gastrointestinal side effects (Williams et al., 1999; Marnett and DuBois, 2002) . A large body of evidence also implicates COX-2 to playing an important role in multiple malignancies, including colon, esophageal, gastric, breast, lung and prostate cancers (Eberhart et al., 1994; Ristimaki et al., 1997; Hida et al., 1998; Wilson et al., 1998; Zimmermann et al., 1999; Gupta et al., 2000; Prescott and Fitzpatrick, 2000) . Accordingly, COX-2-selective inhibitors have shown significant promise as anticancer agents. However, recent clinical trials, although highlighting the cancer-preventive potential of COX-2 inhibitors, have also discovered their adverse cardiovascular effects due to long-term use (reviewed in Grosser et al., 2006) . The molecular mechanisms by which these agents mediate their anticancer or cardiovascular effects remain to be fully elucidated.
We have previously reported that COX-1/-2-selective inhibitor sulindac sulfide and COX-2-selective inhibitor SC-236 upregulated death receptor 5 (DR5) expression (Huang et al., 2001; He et al., 2002a, b) . DR5 is one of the major DRs through which tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) mediates its apoptotic effects. TRAIL is a cytokine that is currently being tested in clinical trials as a novel anticancer agent (reviewed in Huang and Sheikh, 2006) . Our previous results indicated that sulindac sulfide and SC-236 selectively upregulated DR5 and accordingly cooperated with TRAIL to induce apoptosis (Huang et al., 2001; He et al., 2002a, b) . Recently, Liu et al. (2004) have also confirmed that celecoxib, another COX-2 inhibitor similar to SC-236, upregulates DR5 and cooperates with TRAIL to induce apoptosis. It is therefore, evident that COX-2 inhibitors also upregulate DR5 but the molecular mechanisms by which these agents upregulate DR5 remain unknown. Here we report that celecoxib and a novel COX-2 inhibitor ON09310 upregulate DR5 via GADD153/CHOP, a transcription factor that has been implicated in cellular stress response and apoptosis.
Results and discussion
Celecoxib is a well-known COX-2 inhibitor that is currently in clinical use. ON09310 belongs to a novel class of 5-(3-indoyl)-1-(sulfamylphenyl)-3-trifluro-methyl pyrazolines, which function as dual inhibitors of COX-2 and lipoxygenase (Reddy and Reddy, 2002) . The structures of these compounds are given in Figure 1a . Figure 1 also shows that celecoxib and ON09310 upregulated DR5 expression at the mRNA and protein levels in various cell lines representing prostate (DU145 and PC-3) and colon (HCT15 and HCT116) cancers. The fact that these agents upregulate DR5 expression in multiple cell lines indicates that their effect on DR5 regulation is general and not restricted to a single cell line. TRAIL is a ligand for DR5 and in keeping with their effect on DR5 both agents also cooperated with TRAIL to induce apoptosis (Figures 2a and b) . We also investigated their effects in combination with TRAIL on caspases and as is shown in Figure 2c , both celecoxib as well as ON09310 in combination with TRAIL-induced activation of caspases 8, 3 and 9. Overall, we found that, at equimolar concentrations, ON09310 was more potent than celecoxib in upregulating DR5 expression ( Figure 1 ) and these results may explain why ON09310 in combination with TRAIL exhibited stronger apoptotic effects ( Figure 2a) .
Next, we sought to investigate the mechanism by which these agents upregulate DR5. Given that they upregulated DR5 expression at mRNA level, we first investigated whether these agents transcriptionally upregulate the DR5 gene expression and to that end, (310) upregulated DR5 mRNA expression in DU145 and PC-3 human prostate cancer cells. Cells were either left untreated (c) or treated with celecoxib (30 mM) or ON09310 (30 mM) for B24 h and then subjected to northern blotting by standard procedures using a human DR5 cDNA probe. Ethidium bromide staining of the samples shows RNA integrity. (c) Representative western blots show that celecoxib and ON09310 upregulate DR5 protein levels in human prostate and colon cancer cells. DU145 (prostate), HCT15 (colon) and HCT116 (colon) cells were treated with the indicated agents (30 mM for DU145 and 60 mM for HCT15 and HCT116 cells) for B24 h and harvested for western blotting using anti-DR5 monoclonal antibody (Oncogene Science). The same blots were also probed for b-actin as a loading control. ), CX (30 mM) and 310 (30 mM) either singly or in combination as indicated for B8 h. Apoptosis analyses were performed by standard procedures as we have previously described (He et al., 2002a, b) ), CX (30 mM) and 310 (30 mM) either alone or in combination as indicated for B8 h. Western blotting was performed by standard procedures using anti-caspase 8 and 9 antibodies (Stressgen Biotechnologies, Victoria, BC, Canada), and anti-caspase 3 antibody (BD, Franklin, NJ, USA). The same blot was also probed for b-actin as a loading control.
COX-2 inhibitors regulate DR5 expression via GADD153/CHOP Q He et al we analysed their effects on DR5 gene promoter activity. We utilized reporter constructs carrying the proximal 1224 nucleotides corresponding to DR5 promoter region (pGL-A or DR5-full) and two of its deletion variants (pGL-560 and pGL-250) fused to a promoterless luciferase gene (Figure 3a) . The pGL-560 construct harbors proximal 560 nucleotides, whereas pGL-250 contains the most proximal 250 nucleotides of the DR5 promoter. The effect of celecoxib and ON09310 on these reporter constructs was tested in standard luciferase assays and our results indicated that both agents increased DR5 promoter activity from pGL-A (DR5-full) as well as pGL-560 constructs, although ON09310's effect was stronger (Figure 3b) than that of celecoxib (data not shown). Interestingly, however, the reporter construct carrying the most proximal 250 nucleotides (pGL-250) displayed only weak regulation by ON09310 (Figure 3b ) and celecoxib (data not shown). These results therefore indicate that (1) both celecoxib and ON09310 appear to increase DR5 expression, at least in part, via transcriptional regulation, (2) ON09310 is more potent than celecoxib in regulating DR5 promoter activity and (3) the element(s) responsive to these agents reside upstream of -250 bp within the DR5 promoter.
Recently, it has been reported that GADD153/ CHOP, a transcriptional cofactor involved in cellular stress response and apoptosis, binds within the DR5 promoter and mediates endoplasmic reticulum (ER) stress-induced upregulation of DR5 (Yamaguchi and Wang, 2004) . The GADD153/CHOP response element was found to reside at position -271 and -268 within the DR5 promoter (Yamaguchi and Wang, 2004) . Interestingly, our results indicated that the DR5 promoter region (pGL-250) that is devoid of the GADD153/ CHOP response element was not appreciably regulated by these agents (Figure 3) . Next, we sought to investigate whether celecoxib and ON09310 would regulate DR5 expression via GADD153/CHOP. First, we confirmed that indeed GADD153/CHOP activated DR5 gene promoter activity as recently reported (Yamaguchi and Wang, 2004) , and then analysed the effect of celecoxib and ON09310 on GADD153/CHOP expression at the mRNA and protein levels. We reasoned that if these agents were to mediate DR5 upregulation via GADD153/CHOP, then both should also upregulate GADD153/CHOP expression. Figure 4a shows that indeed both agents upregulated GADD153/ CHOP protein levels in DU145, HCT15 and HCT116 human prostate and colon cancer cells; both also upregulated GADD153/CHOP mRNA levels in these cells (data not shown).
Mutation of the GADD153/CHOP response element 'TTGC' (a change from TTGC into 'CATA') has been reported to abrogate GADD153/CHOP-mediated regulation of DR5 promoter activity (Yamaguchi and Wang, 2004) . We therefore, reasoned that if celecoxib and ON09310 upregulate DR5 promoter activity via GADD153/CHOP, then mutation of its response element TTGC should abrogate their effect on DR5 promoter activity. Next, we performed site-directed mutagenesis to replace the GADD153/CHOP response element TTGC with the sequence CATA and tested the effects of celecoxib and ON09310 on the mutant promoter. Figure 4b shows the effect of ON09310 on wild-type and mutant DR5 promoter activity and as is shown, the ON09310 effect was clearly diminished on DR5 promoter harboring the mutated GADD153/ CHOP response element (pGL-A DR5 mut). Similar results were also obtained when celecoxib was used (data not shown). These results therefore, indicate that both agents engage GADD153/CHOP to regulate DR5 promoter activity.
The results presented so far indicate that both celecoxib and ON09310 upregulate DR5 as well as GADD153/CHOP and that both appear to engage GADD153/CHOP to regulate DR5 promoter activity. Next, we investigated the contribution of endogenous GADD153/CHOP in celecoxib and ON09310-mediated upregulation of endogenous DR5. For this purpose, we utilized the RNAi approach to knockdown endogenous GADD153/CHOP and analysed the effects of these agents on endogenous DR5. Figure 4c indicates that RNAi-mediated knockdown of endogenous GADD153/ CHOP significantly diminished DR5 upregulation by both of these agents, thereby further confirming the role of GADD153/CHOP in celecoxib and ON09310-mediated upregulation of DR5.
In this study, we report that celecoxib and a novel COX-2 inhibitor, ON09310, upregulate DR5 expression and that both engage GADD153/CHOP to transcriptionally upregulate DR5 expression. Both also cooperate with TRAIL to induce apoptosis, but ON09310 is considerably more potent than celecoxib. COX-2 inhibitors have shown significant promise as anticancer agents. However, recent clinical trials, although highlighting the Effects of ONO9310 on luciferase activity from the indicated reporter constructs. DU145 human prostate cancer cells were transiently transfected with the indicated constructs and treated with ONO9310 (15 mM) for B24 h. In order to avoid excessive cell death due to higher concentration of ON09310, we used 15 mM ON09310 for B24 h, which proved optimal for luciferase assays. Luciferase assays were performed by standard procedures as previously described (He et al., 2002a, b) . Figure 4 (a) Celecoxib (CX) and ON09310 (310) upregulate GADD153 protein levels in human prostate and colon cancer cells. DU145, HCT15 and HCT116 cells were either left untreated or treated with the indicated agents as described in the legend of Figure 1c , and western blot analyses were performed using anti-GADD153 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The same blots were also probed for b-actin as a loading control. (b) Mutation of the GADD153 response element affects ON09310 regulation of DR5 promoter activity. Schematic of wild-type (pGL-A DR5 wt) and mutant (pGL-A DR5 mut) DR5 promoter-reporter constructs (upper panel). Effects of ONO9310 on luciferase activity from the indicated reporter constructs (lower panel). DU145 human prostate cancer cells were transiently transfected with the indicated constructs and treated with ONO9310 (15 mM) for B24 h and luciferase activity assays were performed. (c) RNAi-based knockdown of endogenous GADD153 diminishes celecoxib and ON09310-mediated upregulation of endogenous DR5 expression. HCT116 cells were transfected with GADD153/CHOP RNAi or control GFP RNAi (GADD153/CHOP, AAGAACCAGCAGAGGUCACAA; GFP, AAGACCCGCGCCGAG GUGAAG (Dharmacon, Chicago, IL, USA). Transfections of RNAi oligonucleotides were performed with LipofectAMINE 2000 (Invitrogen) as per the manufacturer's recommendations with modification using procedures previously described (Yamaguchi and Wang, 2004) . Briefly, a mixture of LipofectAMINE 2000, Opti-MEM (Invitrogen, Carlsbad, CA, USA) and RNAi duplexes was applied to cells growing at B70% confluency in McCoy's 5A medium supplemented with 10% fetal bovine serum. After overnight incubation, cells were washed and either left untreated or treated with celecoxib (60 mM) or ON09310 (60 mM) for overnight and then harvested for western blotting using anti-GADD153 polyclonal and anti-DR5 monoclonal antibodies. We also analysed both agents at lower concentrations (30 mM) and noted that celecoxib had only minimal effect on GADD153 and DR5 expression, whereas ON09310 clearly upregulated both GADD153 and DR5 in cells subjected to GFP RNAi and that upregulation was diminished in GADD153 knockdown cells (data not shown). The same blots were also probed for b-actin as a loading control.
COX-2 inhibitors regulate DR5 expression via GADD153/CHOP Q He et al cancer-preventive potential of COX-2 inhibitors, have also uncovered their adverse cardiovascular effects when administered at high doses for longer terms (reviewed in Grosser et al., 2006) . The molecular mechanisms underlying their anticancer or cardiovascular effects remain unknown. Our findings indicate that both agents engage GADD153/CHOP to regulate the DR5 pathway. GADD153/CHOP functions as a C/EBP homologous transcription factor that has been implicated in ER stress response and apoptosis (reviewed in Oyadomoari and Mori, 2004) . DR5 is a key DR and a bona fide member of the extrinsic pathway of apoptosis (reviewed in Huang and Sheikh, 2006) . These results would suggest that the COX-2 inhibitors used in our study appear to mediate their anticancer effects, at least in part, via these molecules. Whether their COX-2 inhibitory potential is also needed for GADD153/CHOP and DR5 regulation is an important issue that requires more in-depth investigation. However, our present results indicate that both celecoxib and ON09310 also upregulated GADD153/ CHOP and DR5 expression in COX-2-negative HCT15 human colon cancer cells (Figures 1 and 4a) . Furthermore, we have found that just like in other cell lines (Figure 2 ), these agents cooperated with TRAIL to also induce apoptosis in this COX-2-negative cell line (data not shown). These results therefore suggest that COX-2 inhibition may not be a prerequisite for these agents to engage the DR5 pathway. Although the exact molecular mechanism as to how COX-2 inhibitors mediate their adverse cardiovascular effects remains to be elucidated, their ability to inhibit prostacyclin (PGI 2 ) generation in the endothelial cells has been proposed to play a role (Grosser et al., 2006 and references therein). For example, it is believed that in endothelial cells, COX-2-derived PGI 2 serves to protect from thrombosis. Thus, inhibition of PGI 2 by COX-2 inhibitors is believed to predispose to thrombosis and thus, cardiovascular events (Grosser et al., 2006 and references therein) . In view of the toxic effects due to chronic use of COX-2 inhibitors, the utility of low-dose COX-2 inhibitors in combination with other promising agents may prove more effective in managing human malignancies. In this context, our results that COX-2 inhibitors upregulate DR5 and cooperate with its ligand TRAIL to induce apoptosis in various human cancer cells are very relevant. For example, TRAIL is a promising novel anticancer agent with selective toxicity toward cancer cells that is currently being tested in clinical trials (Huang and Sheikh, 2006 and references therein). Agonistic monoclonal anti-DR5 antibodies have also been developed and being evaluated in clinical trials for their anticancer potential (Huang and Sheikh, 2006 and references therein). Our present study, coupled with our previous results (Huang et al., 2001; He et al., 2002a, b) , therefore, form the basis for future in-depth studies to further explore the utility of TRAIL and/or agonistic monoclonal anti-DR5 antibodies in combination with COX-2 inhibitors as a rational approach for cancer prevention and treatment.
